EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access

Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study

Luis Paz-Ares iD, Stephane Champiat iD, W Victoria Lai iD, Hiroki Izumi iD, Ramaswamy Govindan iD, Michael Boyer iD, Horst-Dieter Hummel, Hossein Borghaei iD, Melissa L Johnson iD, Neeltje Steeghs iD, Fiona Blackhall, Afshin Dowlati iD und 13 weitere

Journal of Clinical Oncology · 01.06.2023 · 41 (16) · 2893-2903

DOI: 10.1200/jco.22.02823 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.06.2023. Verfasst von Luis Paz-Ares und 24 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario 12 de Octubre, CNIO-H120 Lung Cancer Unit, Ciberonc and Universidad Complutense, Madrid, Spain. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Antineoplastic Agents, Lung Neoplasms. Die Arbeit wurde bisher 344-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Small-cell lung cancer (SCLC) is an aggressive malignancy with limited treatments. Delta-like ligand 3 (DLL3) is aberrantly expressed in most SCLC. Tarlatamab (AMG 757), a bispecific T-cell engager molecule, binds both DLL3 and CD3 leading to T-cellb–mediated tumor lysis. Herein, we report phase I results of tarlatamab in patients with SCLC. PATIENTS AND METHODS This study evaluated tarlatamab in patients with relapsed/refractory SCLC. The primary end point was safety. Secondary end points included antitumor activity by modified RECIST 1.1, overall survival, and pharmacokinetics. RESULTS By July 19, 2022, 107 patients received tarlatamab in dose exploration (0.003 to 100 mg; n = 73) and expansion (100 mg; n = 34) cohorts. Median prior lines of anticancer therapy were 2 (range, 1-6); 49.5% received antiprogrammed death-1/programmed death ligand-1 therapy. Any-grade treatment-related adverse events occurred in 97 patients (90.7%) and grade b % 3 in 33 patients (30.8%). One patient (1%) had grade 5 pneumonitis. Cytokine release syndrome was the most common treatment-related adverse event, occurring in 56 patients (52%) including grade 3 in one patient (1%). Maximum tolerated dose was not reached. Objective response rate was 23.4% (95% CI, 15.7 to 32.5) including two complete and 23 partial responses. The median duration of response was 12.3 months (95% CI, 6.6 to 14.9). The disease control rate was 51.4% (95% CI, 41.5 to 61.2). The median progression-free survival and overall survival were 3.7 months (95% CI, 2.1 to 5.4) and 13.2 months (95% CI, 10.5 to not reached), respectively. Exploratory analysis suggests that selecting for increased DLL3 expression can result in increased clinical benefit. CONCLUSION In patients with heavily pretreated SCLC, tarlatamab demonstrated manageable safety with encouraging response durability. Further evaluation of this promising molecule is ongoing. [Media: see text]

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaAntineoplastic AgentsLung NeoplasmsHumansLigandsNeoplasm Recurrence, LocalT-LymphocytesMembrane ProteinsIntracellular Signaling Peptides and ProteinsAntibodies, Bispecific

Substanzen

LigandsAntineoplastic AgentsMembrane ProteinsIntracellular Signaling Peptides and ProteinsAMG 757Antibodies, BispecificDLL3 protein, human

Autor:innen und Institutionen

  • Hospital Universitario 12 de Octubre, CNIO-H120 Lung Cancer Unit, Ciberonc and Universidad Complutense, Madrid, Spain.
  • Gustave Roussy, DC(c)partement d'Innovation ThC(c)rapeutique et d'Essais PrC(c)coces (DITEP), Villejuif, France.
  • Thoracic Oncology Service, Department of Medicine, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Divisions of Hematology and Oncology, Washington University Medical School, St Louis, MO.
  • Department of Medical Oncology, Chris O'Brien Lifehouse, Camperdown, NSW, Australia.

ORCID-Profile: Luis Paz-Ares, Stephane Champiat, W Victoria Lai, Hiroki Izumi, Ramaswamy Govindan, Michael Boyer, Hossein Borghaei, Melissa L Johnson, Neeltje Steeghs, Afshin Dowlati, Noemi Reguart, Tatsuya Yoshida, Kai He, Shirish M Gadgeel, Enriqueta Felip, Yiran Zhang, Nooshin Hashemi Sadraei, Taofeek K Owonikoko

Förderung

  • NCI NIH HHS

Zitieren

APA

Paz-Ares, L., Champiat, S., Lai, W. V., Izumi, H., Govindan, R., Boyer, M., Hummel, H. D., Borghaei, H., Johnson, M. L., Steeghs, N., Blackhall, F., Dowlati, A., Reguart, N., Yoshida, T., He, K., Gadgeel, S. M., Felip, E., Zhang, Y., Pati, A., …, & Owonikoko, T. K. (2023). Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. Journal of Clinical Oncology, 41(16), 2893-2903. https://doi.org/10.1200/jco.22.02823

Vancouver

Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, et al. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. Journal of Clinical Oncology. 2023;41(16):2893-2903. doi:10.1200/jco.22.02823

BibTeX
@article{PazAres2023,
  author = {Paz-Ares, Luis and Champiat, Stephane and Lai, W Victoria and Izumi, Hiroki and Govindan, Ramaswamy and Boyer, Michael and Hummel, Horst-Dieter and Borghaei, Hossein and Johnson, Melissa L and Steeghs, Neeltje and Blackhall, Fiona and Dowlati, Afshin and Reguart, Noemi and Yoshida, Tatsuya and He, Kai and Gadgeel, Shirish M and Felip, Enriqueta and Zhang, Yiran and Pati, Amrita and Minocha, Mukul and Mukherjee, Sujoy and Goldrick, Amanda and Nagorsen, Dirk and Hashemi Sadraei, Nooshin and Owonikoko, Taofeek K},
  title = {Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {16},
  pages = {2893--2903},
  doi = {10.1200/jco.22.02823}
}
Kostenlos starten →